Despite its small population, Israel is home to a large concentration of startups. Here is a meeting of the biotech companies that accumulate large sums of money in the Middle Eastern nation.
Historically, Israel’s biotech industry has been seen as secondary to its thriving medical scene. However, despite a population of only nine million, the country has developed a key biotechnology ecosystem over the past decade.
Part of the expansion comes from Israel’s education, which translates into a professional workforce. Another is the importance of new companies in the country in sectors such as agriculture, generation and health. Johnson.
We’ve indexed the five most sensible personal biotech corporations in Israel, judging by how much money they’ve made from investors since 2021. They cover a diversity of verticals, adding healthcare, diagnostics and food technology.
Headquarters: Rejovot
Founded: 2021
1E Therapeutics is a recent addition to the Israeli biotech scene. The company made headlines in 2021 when it won a whopping $120 million circular, the largest of its kind for an Israeli startup in the industry.
1E Therapeutics uses the proceeds to fund the progression of drugs that treat disease through RNA molecules. The company has leading compounds designed to treat indications in oncology, age-related diseases, immunology, antimicrobial resistance, viral infections, and orphan neurological disorders.
The secret society is hiring temporarily and has published some main points about its pipeline.
Headquarters: Rejovot and Jerusalem
Founded: 2018
Future Meat is one of the major players in cultured meat, a form of generation that growers grow meat from animal cells without using classic culture methods.
At the end of 2021, Israeli biotech raised the largest investment circular for the cultured meat sector at the time of $347 million, which only surpassed Upside Foods’ $400 million Series C cycle in 2022.
In Future Meat’s approach, mobiles called fibroblasts are extracted from an animal and grown in a mobile crop. Unlike many companies, which want an animal-based medium for feeding mobile crops, Future Meat claims to be the first to use an animal-free mobile. means of expansion.
Future Meat plans to open its first production facility in the U. S. This year and it’s running for market approval for generation in the U. S. UU. meat. locally and with a much smaller footprint than classic meat production.
First of all, the company plans to launch with cultured poultry meat and then plans to introduce beef and cultured pork. In August 2022, the company produced its first prototype farm lamb.
Headquarters: Haifa
Founded: 2009
MeMed aims to combat the next crisis of antimicrobial resistance by creating diagnostic teams that identify whether an infection is caused by bacteria or viruses. This allows doctors to temporarily prescribe quick remedies for a specific pathogen, rather than giving a patient many medications as a precaution, which can lead to drug resistance.
Instead of looking for pathogen fragments, as many controls do, MeMed’s BV control measures the immune system’s reaction to infection through the detection of immune proteins called TRAIL, IP-10, and CRP. By processing a blood pattern for 15 minutes, the control can determine whether the infection is bacterial or viral.
MeMed’s BV test was illuminated in the United States. The company is also marketing a COVID-19 test in Europe that allows healthcare professionals to know which Covid patients may get worse.
In January 2022, MeMed raised $93 million in a Series E to fund the commercialization of its diagnostic tool, overcoming demanding production situations and expanding its offerings to cover a wide variety of disease indications.
Headquarters: Rehovot and San Diego, USA
Founded: 2008
Nucleix drew attention when it raised a $55 million investment circular in early 2021. The Israeli biotech startup used the cash to fund the blood progression of cancer patients, also known as liquid biopsy.
Liquid biopsies are an emerging generation that allows the detection of symptoms of cancer in the blood without tissue biopsies, invasive and uncomfortable for patients. However, some liquid biopsy tests, which detect total cells or DNA fragments, can be expensive lately. and difficult to implement because they depend on the remedy in the central laboratories.
Nucleix’s solution is a cost-effective test that runs on undeniable lab equipment and can roll back the effects in a single day. The generation filters chemical changes called methylation of DNA molecules. Since cancer causes changes in methylation patterns in the genome, reading those patterns may only reveal the cancer’s fingerprints at a very early stage.
Nucleix checks bear the EpiCheck logo and your first check is advertised in Europe for the screening of number one and recurrent bladder and upper urinary tract cancer. Nucleix is also applying to get approval for a similar check for lung cancer.
Headquarters: Rejovot
Founded: 2019
Remilk aims to expand a sustainable option to classic milk production, which consumes many resources and emits many greenhouse gases. Instead of creating a plant-based milk replacement, Israeli biotechnology plans to produce genuine milk with genetically modified yeast.
In January 2022, the company raised a massive Series B circular investment valued at $120 million to fund the progress of its technology. The company also built what it calls the world’s largest large-scale precision fermentation facility as part of the Symbiosis project, a commercial ecosystem in Denmark.
In June 2022, Remilk’s product won the green award for sale in the United States and the company plans to start advertising operations in the coming months. In addition, Remilk signed a pact with the giant CBC Group to launch a dairy product line created from Remilk’s animal-free milk in Israel, pending regulatory approval.
With its thriving biotech startup scene, Israel remains a key region to watch in the global biotech industry.
Labiotech. eu is the main virtual medium covering the biotech industry.
More than 150,000 visitors a month use it to keep abreast of biotechnological activity and innovations. I hope you enjoy reading our stories!
Search for a topic, country, or corporate call in the search field